Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs)

A technology of Bacteroides fragilis and inflammatory bowel disease, applied in the field of microorganisms, can solve problems such as inflammatory bowel disease that have not been seen

Active Publication Date: 2016-03-30
GUANGZHOU ZHIYI PHARMA INC
View PDF3 Cites 41 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0030] Bacteroides fragilis ZY-312, which was screened out earlier, has been confirmed by in vivo and in vitro experiments. In addition to good preventive and therapeutic effects on antibiotic-associated diarrhea, obesity, diabetes, and meningitis, this strain has no other effects. Relevant studies and reports of excellent resistance to inflammatory bowel disease, especially ulcerative colitis or Crohn's disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs)
  • Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs)
  • Application of bacteroides fragilis to prevention and/or treatment of inflammatory bowel diseases (IBDs)

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0056] Cultivation of Bacteroides fragilis ZY-312

[0057] 1. The names of the reagents and instruments used are as follows:

[0058]

[0059] 2. Viable bacteria counting method

[0060] The count of live bacteria adopts the 10-fold serial dilution method:

[0061] Take 100 μL of the bacterial solution and add it to 900 μL of medium, and gradually dilute to an appropriate concentration. 4 concentration gradients were spotted on each plate, and each gradient was spotted 3 times, each spotting 20 μL. In a biochemical incubator at 37° C. for anaerobic culture for 48 hours, the number of colonies was counted (counted in a concentration gradient with the number of colonies ranging from 3 to 30).

[0062] The number of viable bacteria (CFU / mL) = the sum of three spotted colonies / 3 × 50 × dilution

[0063] 3. Training method

[0064] Step 1: Take a freeze-dried and preserved strain (ZY-312, Bd-312 or ATCC25285, the culture method is the same, so I will not list them one by ...

Embodiment 2

[0069] Effect of Bacteroides fragilis ZY-312 on experimental colitis in rats

[0070] Select 70 healthy and mature SD rats, half male and half male, body weight 200±20g, purchased from Guangdong Experimental Animal Center, raised in SPF grade animal room, randomly divided into 7 groups, 10 rats in each group, all rats before experiment Adapt to the environment for 1 week, and feed normal rat chow.

[0071] Using 5% DSS (dextransulfatesodium, DSS, purchased from Sigma, USA) solution to induce rat chronic ulcerative colitis model, 70 SD rats were randomly divided into the following 7 groups:

[0072] Normal control group, model group, mesalazine group, ZY-312 group, Bd-312 group, ATCC25285 group and combination group (ZY-312+mesalazine), the efficacy of each intervention group was detected by DAI score and tissue injury score . The animal grouping table is as follows:

[0073] Numbering

modeling

group

number of animals

[0074] A

no ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of bacteroides fragilis ZY-312 to prevention and / or treatment of inflammatory bowel diseases (IBDs), including an application of bacteroides fragilis ZY-312 to preparation of medicines, medicine compositions, food, health care products, food additives, and the like for preventing and / or treating IBDs. In vivo and in vitro related experiments confirm that bacteroides fragilis ZY-312 has excellent resistance to the IBD, including ulcerative colitis or the Crohn's disease, does not have toxic or side effect and can be permanently and effectively applied to preparation of the medicines, medicine compositions, food, health care products or food additives for preventing and / or treating IBDs. The medicines, medicine compositions, food, health care products or food additives can be used for preventing and treating IBDs and have important application values.

Description

technical field [0001] The invention relates to the technical field of microorganisms, especially the application of Bacteroides fragilis ZY-312 in the prevention and / or treatment of inflammatory bowel disease, including the application of preparing medicine, pharmaceutical composition, food, health care products and food additives. Background technique [0002] Inflammatory bowel disease (Inflammatory bowel disease, IBD) is a group of unknown causes of chronic intestinal inflammatory diseases, including ulcerative colitis (Ulcerativecolitis, UC) and Crohn's disease (Crohn'sdisease, CD). The former, also known as nonspecific ulcerative colitis, is an inflammation of the rectum and colon of unknown cause, and the lesions are mainly limited to the mucosa and submucosa of the large intestine. The latter is a kind of chronic granulomatous inflammation, and the lesions can involve various parts of the gastrointestinal tract, mainly in the terminal ileum and the adjacent colon, mo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/74A61P1/00A61P1/04A23L33/135
CPCA61K35/74A23L33/135C12N1/205C12R2001/01
Inventor 智发朝白杨王晔刘洋洋王从峰
Owner GUANGZHOU ZHIYI PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products